先声药业2023年度报告

24567397297106113114115117119121230 (1)(2) (1) (2) (3)(2) (1)20231 1820233 31(2)20231182023331(3)20233 31 公司資料 183171712-1716 30 53 20E7703 108 699-18 http://www.simcere.com 2096 202312 31 •66.08202263.244.5%65.670.280.13•47.5672.0%202241.2815.2%•19.6929.8%202213.1%15.7623.9%202210.2%14.1521.4%202210.5%16.4824.9%202222.3%•15.63202217.281.659.6%223.7%202227.3%•7.1520229.312.1623.2%•0.2720220.3625.0% 公司概覽 202312311410040NRDL TCENKCEAIADC202312 311,000170490 202312314,200322,80017,000200 GMPGMPFDA (SAB) 2024®®®NDA®2.0 7035%72% 20233CL®BD/ 管理層討論及分析 202380 202312 3172.0% •®®1075,000®NDA2023628TASTETASTE II TASTE-SL® •®20231027®PD-(L)1® •®21%DMARDs •20231 283CL®202312®NRDL2024 2®NMPA®313063,80067 6015 •NDAIII1®®®® •POC20231231PCC2IND34FIH5 5FIHSIM023738SIM0348330®73SIM0278826®961130 管理層討論及分析 •®®SIM0235TNFR2SIM0237PDL1/IL-15vSIM0501USP1SIM0500GPRC5D-BCMA-CD3 IIIIII •202413®IIISCORES2024311NMPA®20243 15®PROCVEGF •20241 18(The New England Journal of Medicine)®II/IIICOVID-19® •20242 19(JAMA NEUROLOGY)®AISIIITASTE-SL®90mRS0~164.4% vs. 54.7% 2.0 •®202312 20NMPA®•12 202312 31 •2023818®(CMAB009)20233®NMPA•20231010ADC189•20231121(IL-4R)• •19.60202219.381.2%29.7%202230.6%0.9•15.63202217.289.6%23.7%202227.3%3.6•3.9720222.1089.4%6.0%20223.3%2.7 管理層討論及分析 20242.0 (BD) 6015NDAIII1I/II1240ADC 管理層討論及分析 管理層討論及分析 2023123147.5672.0% ® ®20207202012STROKE®IIITASTE®90mRS0-1® (ESOC)(AHA)(WCN) •2023427®ICHNMPAII •20237 3IIFPI80 •2023519100®TASTE II®AIS1,30024AIS20242TASTE IIStroke and Vascular NeurologyTASTE II •20236 2422019TASTEAIS®IIa •20237 4RWSEXPAND4,750AIS2024(ESOC) 202312 31®1075,000 管理層討論及分析 ® ®2017CSCONSCLC •20236ASCO®®PD-1NSCLC®NSCLCNSCLC •20237 42023NSCLC2022 •20237 182023PS0~112A •2023923(WCLC)®ENPOWER®PD-1EGFR/ALKNSCLC®NSCLC •2023122023® •20241® ® PD-(L)1PD-(L)12020330 •20231ASCO®(1)CAPEOXMSS(2)TACEIICISLD-12 •20234®CSCOCSCO2023I2ACSCO2023II2ACSCO2023I2ACSCO2023IICSCO2023IICSCO2023III2B 管理層討論及分析 •20234 132023CN006MSI-H/dMMR2B •20236ASCO®SOXPD-L1 •20237317(2023)®MSI-H/dMMR2B •2023923(WCLC)®Endouble®®PD-L1≥1%NSCLCPD-L1NSCLC®®-NSCLCNSCLC®ES-SCLCES-SCLC •202310(ESMO)®®IINSCLC®PD-1NSCLC® ® 46 (CDK4/6)First-in-classG120208G1Therapeutics, Inc.G1 ®20212 13FDA(NCCN)CSCO •2023510G1IITNBC®ADC50% •20235British Journal of Clinical Pharmacology(240mg/m2) •2023511(ESMO BC)SGmTNBCIISGmTNBC(AEs) •20235 25Frontiers in PharmacologyMeta(SN)(FN)CIM(G-CSF) 管理層討論及分析 •2023659ASCOTNBCES-SCLC•20237 182023®1•20238 14®NMPAES-SCLC®ES-SCLC•20239•202310®ES-SCLCTRACES(ESMO)•202310 27®NMPA•202312 20®NMPA® ® 1.1®2017 •20235312023EULAR RA(OA)RA(ILD) 20238(UIP)Frontiers in ImmunologyRARA-UIPRA-UIP/(csDMARDs) 2023920231120232023 管理層討論及分析 ® ®SARS-CoV-23CL20211117 •2023128®NMPAH20230001COVID-19 •20232 8® •202332® •20233 21®105FPI202351637SIM0417I •20234 11®108FPI202361514SIM0417I •20234®COVID-19≥65—®2,200 •20236152023® •20237 11®COVID-19Ib(NCT05369676)TheLancet Regional Health – Western Pacific(DOI: 10.1016/j.lanwpc.2023.100835) •2023824CDE®25°C30°C1218 •20239 19COVID-19®70.1COVID-191 •2023930I(NCT05339646)European Journal of Pharmaceutical Sciences(DOI: 10.1016/j.ejps.2023.106598) •20231013®NatureCommunications(DOI: 10.1038/s41467-023-42102-y •202312132023®®47920241 1 管理層討論及分析 •20241 18(The New England Journal of Medicine)®COVID-19II/III(NCT05506176)(DOI:10.1056/NEJMoa2301425) 202281920221216351,208®750mg+100mg25603605COVID-19® (1)11COVID-19COVID-1972mITT1®35.8COVID-19®60.4 (2)mITT15®96.9%-1.51log10mL (3)®® 351,09295.9%87476.7%®®3CL •20242 2®NMPA NDA ® ®AIS®® •2023628®NDANMPAAIS •20231128®INDNMPAAISPSCI •20242 19JAMA NEUROLOGY29.0®IIITASTE-SL®AIS®90mRS0~164.4% vs. 54.7%OR=1.50 95% CI 1.15~1.95 P=0.003≤65>65≤24h>24h®®AIS90(AE) 管理層討論及分析 ® Apexigen, IncPyxis Oncology, IncVEGFIb •2023627IIISCORESLPI55421 •20241 3SCORESPFSOS(1) SCORES(BIRC)RECIST1.1PFSPFSPFSPFSBIRC(2) OSOS(3) •20243 15®NMPA ®(EGFR)1 EGFRFOLFIRImCRC20233®mCRCEGFR •20238 18® III (DORA) Idorsia Pharmaceuticals Ltd.IdorsiaDORAABIII1312(EMA)DORA 管理層討論及分析 •2023720NMPA •202311 30IFPI •202312 17IIIFPI33 •20243 15III205(LPI) LNK01001 (JAK1)1 LNK01001JAK1(RA)(AS)(AD)3IIJAK20223 18LNK01001 •20238 23LNK01001(AS)II•202312 20LNK01001bDMARDsIIIFPI ADC189 (PA)1 ADC189(PA)CAP—(CEN)ADC189ADC189ADC18924 •20231010ADC189ADC189III •20242ADC189ADC189(BA)III II (IL-4R)2 IL-4RIL-4RIL-4IL-13IL-4RIL-4IL-13Th2Th2 •202311 21 管理層討論及分析 SIM0270 (SERD) SERDSIM0270SERD •202323SIM0270NMPA SIM03351 IL-17ASIM0335(CKBA)I •2023112SIM0335IIaSIM0335 •20233 250% I SIM0235TNFR2 G1IgG12TNFR2PD-1SIM0235TNFR2(ADCC)(ADCP)FcTNFR2TregMDSC(TNF)TNFR2TNFR2TNFR2+TregMDSCSIM0235TNFR2FcTNFR2 •2023313SIM0235PD-1KEYTRUDAR•SIM0235T(CTCL) I SIM0237PD-L1/IL15v SIM0237PD-L1IL-15/IL-15RsushiPD-L1PD1/PD-L1IL-15SIM0237PD-L1IL-15 •20233 8SIM0237IFPISIM0237MRCT 管理層討論及分析 •20231015SIM0237NMPANMIBC •20241 23SIM0237NMIBCFPI SIM0501USP1 1USP1USP1DNAUSP1HRDUSP1PARPPARPiSIM0501PARPiHRD •202312 2SIM